ReviewTherapeutics and clinical risk management2020

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis.

Charlotte Näslund-Koch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.